Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines
- 28 February 2019
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (7) , E267-E269
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatmentJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2018
- A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisionsJournal of the European Academy of Dermatology and Venereology, 2017
- Methods report: European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPCJournal of the European Academy of Dermatology and Venereology, 2017
- British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017British Journal of Dermatology, 2017
- Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”Archives of Dermatological Research, 2016
- Use of biologics for psoriasis in Central and Eastern European countriesJournal of the European Academy of Dermatology and Venereology, 2015
- Can We Rely on the Dermatology Life Quality Index as a Measure of the Impact of Psoriasis or Atopic Dermatitis?Journal of Investigative Dermatology, 2012
- Psychometric Properties of the Dermatology Life Quality Index (DLQI) in 900 Italian Patients with PsoriasisActa Dermato-Venereologica, 2005
- The Norwegian Version of the Dermatology Life Quality Index: a Study of Validity and Reliability in PsoriaticsActa Dermato-Venereologica, 2002
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994